We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Minnesota Republican Gov. Tim Pawlenty, a staunch advocate for reducing Rx drug costs through importation, is seeking federal permission to join the multistate Medicaid drug purchasing pool approved by HHS Secretary Tommy Thompson last week.
HHS is creating a new task force to determine ways to help speed the development of new medical technologies and drug compounds, Secretary Tommy Thompson said in a speech earlier this week.
Drugmakers could have to fork over another $37 million a year or more in Medicaid drug rebates if states take the advice of the HHS Office of Inspector General (OIG) and start billing manufacturers for rebates on physician-administered drugs.
Two major drug manufacturers have decided to offer free drugs to some low-income seniors under the new Medicare discount drug card program set to take effect in June.
Drugmakers should expect to see the new methodology for determining the average sales price (ASP) of drugs spread to state Medicaid programs and commercial payers, despite continuing confusion in the industry about how ASP will be calculated for the purpose of setting Medicare Part B reimbursements, according to drug price-reporting experts.
Government officials are faced with the daunting task of finding a solution to rising Rx drug prices while maintaining public safety and perpetuating a positive and fruitful working relationship between the pharmaceutical industry and regulatory agencies.
Pfizer yesterday became the first major drugmaker to announce it is partnering with a major healthcare company in offering a discount card under the new Medicare program set to kick off in June.
HHS Secretary Tommy Thompson yesterday approved plans allowing five states to pool their purchasing power to obtain deeper discounts from drugmakers on prescription drugs bought under the Medicaid program.
At least two major drug manufacturers will offer assistance – including free drugs – to some low-income seniors under the new Medicare discount drug program set to take effect in June.
Despite continuing confusion in the industry about how the average sales price (ASP) of drugs will be calculated for the purpose of setting Medicare Part B reimbursements, drugmakers should expect to see the new ASP methodology spread to state Medicaid programs and commercial payers, according to drug price-reporting experts.